HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
Eric Van Cutsem(Universitair Ziekenhuis Leuven), Josef Rüschoff(University of Kassel), Jian Xu(University of California, Los Angeles), Keun-Wook Lee(Seoul National University Bundang Hospital), Shunchang Jiao(Chinese PLA General Hospital), Yung‐Jue Bang(Seoul National University), Oleg Gladkov(Chelyabinsk Regional Clinical Oncology Center), Timothy Price(Basil Hetzel Institute), J. León Chong(Instituto Nacional de Enfermedades Neoplásicas), Roberto I. López-Sanchez(Hospital Punta Pacifica), Michaela Lehle(Roche (Switzerland)), Oliver Stoß, Astrid Kiermaier(Uppsala University Hospital), Vivian Ng, Julie Hill(Roche (Switzerland)), Marlène Thomas(Roche Pharma AG (Germany)), Feng-yi Feng(Peking University)
Cited by 615
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k